Sarepta Therapeutics has commenced subject screening for its Phase III EMERGENE clinical trial (Study SRP-9003-301) of investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) in treating limb-girdle muscular dystrophy Type 2E (LGMD2E/R4) or beta sarcoglycanopathy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,